Professor C. Anthony Hunt, a founding member of the Pharmaceutical Sciences and Pharmacogenomics (PSPG) Program at UCSF (see http://www.ucsf.edu/dbps/pspg.html ), joins the Board of Advisors of HelixoMetry, Inc., a Siliconvalley Bioinformatics Intellectual Portfolio. He was attracted most particularly by Helixometry’s FractoGene (patent pending) to mathematically interpret 98.7% of the human DNA, for an undisclosed equity. Dr. Hunt heads a “top 10” lab of the UC system, and is a PSPG leader with a slew of issued pharma patents, while featuring fractals, see http://biosystems.ucsf.edu/default.htm.
FOR IMMEDIATE RELEASE
CONTACT:
Andras J. Pellionisz, Ph.D.
Founder & CEO of HelixoMetry, inc.
935 Rosette Court
Sunnyvale, CA 94086
Phone: 408-891-7187
http://helixometry.com
http://fractogene.com
cob@helixometry.com
Sunnyvale, CA – April 15, 2003 -- HelixoMetry, Inc. announces that its “FractoGene” (patent pending) on the mathematical language of genetic code attracted Prof. C. Anthony Hunt, (see CV http://biosystems.ucsf.edu/People/CAHunt/CAHCV.html) to become Board of Advisors Member of HelixoMetry, Inc.
Professor Hunt writes in his “Observations” http://biosystems.ucsf.edu/Observations/New.html
“Biotechnology companies are increasing the productivity …to deliver new, safer and more effective drugs, and to maintain competitive growth. .. The pharmaceutical industry will face additional challenges with the continuing climate of mergers and acquisitions, which is certain to put extra burdens on the industry's resources due to the increasing need for research by cross-functional teams, remote geographical locations, diverse scientific and cultural backgrounds, and the diverse processes of the entrepreneurial segment of the business. To meet this challenge it is imperative that companies leverage all the available knowledge, particularly at the intersection of experimentation, bioengineering, simulation, modeling, and informatics. ... A critical factor for future success will be to find an efficient way to provide all decision makers, bench scientists, engineers, R&D managers, and business development, licensing executives, etc...Within the decade, … the number of potential molecular therapeutic targets will increase by a factor of 10 to 60.”
The companies that will benefit most will be those that adopt a more systematic, computationally enhanced approach to drug discovery supported by an underlying, integrated engineering and informatics framework.
The future of the healthcare enterprise and its impact on human health will be dependent on how well the next generation of scientists is able to integrate all the technology domains across the R&D cycle into an integrated, informed strategy for drug discovery and realization.
Those individuals who understand this biological and medical informatics imperative and are willing to adopt new technologies and mind-sets to help bring it to fruition will become the new leaders”
About HelixoMetry and FractoGene
HelixoMetry introduced a break-through mathematical algorithm to decipher the genetic code, as „geo-metry” (suitable to measure Geos, the Globe) is inappropriate to mathematically characterize the double helix and to crack the genetic code.
When the human genome was mapped out little over a year ago, up to 98.7% of the DNA was found to contain, instead of genes, so-called non-coding sequences, junk genes” – says András Pellionisz, inventor of FractoGene. „One person’s junk is an other person’s treasure”, he continues. Now he is proud to have incorporated his HelixoMetry Company, and to have submitted a Provisional patent application to protect FractoGene, his invention for the mathematical language of highly repetitious genetic code. At the “Time Magazine Summit”, a celebration of the past 50 years of the DNA, Dr. Pellionisz, Founder and CEO of HelixoMetry, and inventor of FractoGene pointed out that the notion, “the next 50 years of the DNA will bring a fusion of biotech, nanotech, infotech” will depend on relating the 100%, the coding and non-coding DNA by mathematical paradigms suitable for engineering, e.g. FractoGene. He added that the recently found 99% homology of the gene pool between DNA of the mouse and the human points directly to the 800 Mb of extra “junk DNA” to make us human, as well as pointed out that e.g. Friedreich’ disease is caused by a “running triplet” in an intron.
The extraordinary interest in HelixoMetry and FractoGene not only attracted Prof. Hunt as a Board of Advisor Member, but also resulted in major leaps, to be announced separately.